Mark Tuthill

589 total citations
15 papers, 248 citations indexed

About

Mark Tuthill is a scholar working on Surgery, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Tuthill has authored 15 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Tuthill's work include Ovarian cancer diagnosis and treatment (4 papers), Intraperitoneal and Appendiceal Malignancies (3 papers) and Testicular diseases and treatments (2 papers). Mark Tuthill is often cited by papers focused on Ovarian cancer diagnosis and treatment (4 papers), Intraperitoneal and Appendiceal Malignancies (3 papers) and Testicular diseases and treatments (2 papers). Mark Tuthill collaborates with scholars based in United Kingdom, United States and Greece. Mark Tuthill's co-authors include Dee Short, Michael J. Seckl, Philip Savage, Peter Dráber, Julia Zinngrebe, Thomas Newsom-Davis, Antonella Montinaro, Henning Walczak, Jonathan D. Graves and Katharina Prieske and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and British Journal of Cancer.

In The Last Decade

Mark Tuthill

14 papers receiving 242 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Tuthill United Kingdom	8	86	67	55	47	45	15	248
Hanjin Yang China	8	48 0.6×	34 0.5×	49 0.9×	40 0.9×	23 0.5×	22	234
Martin Koch Germany	8	64 0.7×	51 0.8×	61 1.1×	17 0.4×	22 0.5×	18	254
Ignacio Cristóbal García Spain	9	45 0.5×	55 0.8×	45 0.8×	83 1.8×	44 1.0×	39	313
Pei‐Chi Kao United States	8	75 0.9×	41 0.6×	42 0.8×	20 0.4×	42 0.9×	28	230
Franca Sartor Italy	8	88 1.0×	41 0.6×	83 1.5×	74 1.6×	12 0.3×	13	283
Stefan Gysler United States	9	64 0.7×	25 0.4×	21 0.4×	57 1.2×	104 2.3×	19	303
Suk Bong Koh South Korea	10	35 0.4×	79 1.2×	154 2.8×	49 1.0×	58 1.3×	29	338
Akira Yabuno Japan	11	52 0.6×	38 0.6×	79 1.4×	26 0.6×	30 0.7×	37	322
Muhammad Ashar Ali United States	9	63 0.7×	35 0.5×	73 1.3×	17 0.4×	17 0.4×	41	298
Francesca Colonese Italy	10	64 0.7×	34 0.5×	171 3.1×	28 0.6×	57 1.3×	24	367

Countries citing papers authored by Mark Tuthill

Since Specialization

Citations

This map shows the geographic impact of Mark Tuthill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Tuthill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Tuthill more than expected).

Fields of papers citing papers by Mark Tuthill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Tuthill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Tuthill. The network helps show where Mark Tuthill may publish in the future.

Co-authorship network of co-authors of Mark Tuthill

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Tuthill. A scholar is included among the top collaborators of Mark Tuthill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Tuthill. Mark Tuthill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Atkins, Michael B., Pooja Ghatalia, Jaime R. Merchan, et al.. (2024). Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.. Journal of Clinical Oncology. 42(16_suppl). 4534–4534. 1 indexed citations

Challapalli, Amarnath, John McGrane, Sarah Kingdon, et al.. (2022). 1457P A UK multicentre retrospective review of metastatic renal cell carcinoma (mRCC) patients (pts) outcomes with brain metastases (BM) in the modern era. Annals of Oncology. 33. S1211–S1211. 2 indexed citations

Castellano, Daniel, Rafael Morales‐Barrera, Ignacio Durán, et al.. (2019). Interim analysis of ibrutinib plus paclitaxel for patients with metastatic urothelial carcinoma previously treated with platinum-based chemotherapy.. Journal of Clinical Oncology. 37(7_suppl). 365–365. 1 indexed citations

Watson, Robert, Robert D. Morgan, Johnson Joseph, et al.. (2018). Bilateral Testicular Germ Cell Tumors: A Case-Series From a UK-Based Tertiary Referral Center Over 19 Years. Clinical Genitourinary Cancer. 16(3). e513–e516. 4 indexed citations

Tyrrell, Helen E.J., David N. Church, Johnson Joseph, et al.. (2017). Changing Practice Evaluation—Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols—Experience From a Supraregional Center. Clinical Genitourinary Cancer. 16(3). 240–244. 7 indexed citations

Purshouse, Karin, Anna Schuh, Benjamin P. Fairfax, et al.. (2017). Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer. Molecular Case Studies. 3(3). a001362–a001362. 8 indexed citations

Savage, Philip, et al.. (2015). Brain metastases in gestational trophoblast neoplasia: An update on incidence, management and outcome. Gynecologic Oncology. 137(1). 73–76. 46 indexed citations

Tuthill, Mark, Antonella Montinaro, Julia Zinngrebe, et al.. (2014). TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene. 34(16). 2138–2144. 65 indexed citations

Fenu, Elisabetta, Ho Kwong Li, R. Burt, et al.. (2012). Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer. British Journal of Cancer. 107(6). 925–930. 23 indexed citations

10.

Alifrangis, Constantine, et al.. (2011). New drugs for prostate cancer. British Journal of Urology. 109(12). 1801–1806. 4 indexed citations

11.

Syed, Nelofer, Paul J. Smith, Beverly E. Griffin, et al.. (2010). DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma. British Journal of Cancer. 103(2). 265–274. 25 indexed citations

12.

Krell, Jonathan, et al.. (2010). The cost of a QALY. QJM. 103(9). 715–720. 24 indexed citations

13.

Tuthill, Mark, Adrian Lim, Mihir Gudi, et al.. (2009). Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis. European Journal of Cancer. 45(12). 2146–2149. 31 indexed citations

14.

Tuthill, Mark, Rosa Giuliani, Jacqueline S. Lewis, et al.. (2009). Peritoneal disease in breast cancer: A specific entity with an extremely poor prognosis. Journal of Clinical Oncology. 27(15_suppl). e12023–e12023. 1 indexed citations

15.

Tuthill, Mark, et al.. (2006). Calcific uremic arteriolopathy presenting with small and large bowel involvement. Journal of Nephrology. 19(1). 115–118. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact